The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,007
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q. F., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 204
Ge, R., Wang, Z., & Liang Cheng, C. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00272-w · Cited by 212
Complexities of Prostate Cancer
Wasim, S., Lee, S., & Kim, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214257 · Cited by 226
“The most frequently mutated DDR genes in both the germline and the somatic cells of mCRPC are BRCA2, ATM, and CHK2 [56,67].”
InfluentialShu, F., Han, X., Li, Q.-N., Ren, X., Liu, Z., Hu, B., Wang, H., Wang, H., & Jiang, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01300-8 · Cited by 203
A basal stem cell signature identifies aggressive prostate cancer phenotypes
Smith, B. A., Sokolov, A., Uzunangelov, V., Baertsch, R., Newton, Y., Graim, K. S., Mathis, C., Cheng, D., Stuart, J. M., & Witte, O. N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518007112 · Cited by 196
Teply, B. A., Wang, H., Luber, B. S., Sullivan, R., Rifkind, I., Bruns, A. B., Spitz, A. N., Decarli, M., Sinibaldi, V. J., Pratz, C. F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30906-3 · Cited by 193
ONECUT2 Is a Targetable Master Regulator of Lethal Prostate Cancer That Suppresses the Androgen Axis
Rotinen, M., You, S., Yang, J., Coetzee, S. G., Reis-Sobreiro, M., Huang, W., Huang, F., Pan, X., Yáñez, A., Hazelett, D. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0241-1 · Cited by 192
Self-citationShang, Z., Yu, J., Sun, L., Tian, J., Zhu, S., Zhang, B., Dong, Q., Jiang, N., Flores‐Morales, A., Chang, C., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz108 · Cited by 191
Smith, M., Scher, H., Sandhu, S., Efstathiou, E., Lara, P. N., Yu, E., George, D., Chi, K., Fred Saad, C., Ståhl, O., et al. (2022) · Research at the University of Copenhagen (University of Copenhagen) · doi:10.1016/s1470-2045(21)00757-9 · Cited by 182
Self-citationJanoušková, H., Tekle, G. E., Bellini, E., Udeshi, N. D., Rinaldi, A. M., Ulbricht, A., Bernasocchi, T., Civenni, G., Losa, M., Svinkina, T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4372 · Cited by 185
Self-citationReina‐Campos, M., Linares, J. F., Durán, Á., Cordes, T., L’Hermitte, A., Badur, M. G., Bhangoo, M. S., Thorson, P. K., Richards, A. C., Rooslid, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.018 · Cited by 188
Self-citationCirculating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Vandekerkhove, G. R., Struss, W. J., Annala, M., Kallio, H. M. L., Khalaf, D. J., Warner, E. W., Herberts, C., Ritch, E. J., Beja, K., Loktionova, Y., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.12.042 · Cited by 190
Transcriptional mediators of treatment resistance in lethal prostate cancer
He, M. X., Cuoco, M. S., Crowdis, J. P., Bosma-Moody, A., Zhang, Z., Bi, K., Kanodia, A., Su, M.-J., Ku, S., Garcia, M. M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01244-6 · Cited by 186
Self-citation2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
Blomme, A., Ford, C. A., Mui, E. J., Patel, R., Ntala, C., Jamieson, L. E., Planque, M., McGregor, G. H., Peixoto, P., Hervouet, É., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16126-7 · Cited by 184
Scher, H. I., Graf, R. P., Schreiber, N. A., McLaughlin, B., Lu, D. M., Louw, J. E., Danila, D. C., Dugan, L., Johnson, A. D., Heller, G., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.11.024 · Cited by 185
Self-citationStopsack, K. H., Nandakumar, S., Wibmer, A. G., Haywood, S., Weg, E. S., Barnett, E. S., Kim, C. J., Carbone, E. A., Vasselman, S. E., Nguyen, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0168 · Cited by 180
Self-citationAntonarakis, E. S., Lu, C., Luber, B. S., Liang, C., Wang, H., Chen, Y., Silberstein, J. L., Piana, D., Lai, Z., Chen, Y., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.035 · Cited by 180
Self-citationRao, S. R., Snaith, A. E., Marino, D., Cheng, X., Lwin, S. T., Orriss, I. R., Hamdy, F. C., & Edwards, C. M. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.402 · Cited by 179
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
Antonarakis, E. S., Armstrong, A. J., Dehm, S. M., & Luo, J. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.17 · Cited by 181
A novel approach for data integration and disease subtypingPreprint
Nguyen, T., Tagett, R., Diaz, D., & Drăghici, S. (2017) · Genome Research · doi:10.1101/gr.215129.116 · Cited by 183
Antonarakis, E. S., Shaukat, F., Velho, P. I., Kaur, H. B., Shenderov, E., Pardoll, D. M., & Lotan, T. L. (2018) · European Urology · doi:10.1016/j.eururo.2018.10.009 · Cited by 179
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Wadosky, K. M., & Koochekpour, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10901 · Cited by 179
Latonen, L., Afyounian, E., Jylhä, A., Nättinen, J. E., Aapola, U., Annala, M., Kivinummi, K. K., Tammela, T. L. J., Beuerman, R. W., Uusitalo, H. M. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03573-6 · Cited by 181
Laere, B. D., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P., Oyen, P. V., Ghysel, C., Ampe, J., Ost, P., Demey, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1943 · Cited by 177
Henzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13668 · Cited by 173
Self-citationRedirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Li, Z., Alyamani, M., Li, J., Rogacki, K. R., Abazeed, M. E., Upadhyay, S. K., Balk, S. P., Taplin, M., Auchus, R. J., & Sharifi, N. (2016) · Nature · doi:10.1038/nature17954 · Cited by 175
Self-citationDiverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J. M., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 180
Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer
Kang, J., Manna, F. L., Bonollo, F., Sampson, N., Alberts, I., Mingels, C., Afshar‐Oromieh, A., Thalmann, G. N., & Karkampouna, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.015 · Cited by 185
Hao, H.-X., Jiang, X., & Cong, F. (2016) · Cancers · doi:10.3390/cancers8060054 · Cited by 180
SOX9 drives WNT pathway activation in prostate cancer
Ma, F., Ye, H., He, H. H., Gerrin, S. J., Chen, S., Tanenbaum, B., Cai, C., Sowalsky, A. G., He, L., Wang, H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci78815 · Cited by 170
Self-citationSystematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
Kim, E., Ilić, N., Shrestha, Y., Zou, L., Kamburov, A., Zhu, C., Yang, X., Lubonja, R., Tran, N. H., Nguyen, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0160 · Cited by 172
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 177
Development of a stress response therapy targeting aggressive prostate cancer
Nguyen, H. G., Conn, C. S., Kye, Y., Xue, L., Forester, C. M., Cowan, J. E., Hsieh, A. C., Cunningham, J. T., Truillet, C., Tameire, F., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar2036 · Cited by 164
Non-canonical functions of the RB protein in cancer
Dick, F. A., Goodrich, D. W., Sage, J., & Dyson, N. J. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0008-5 · Cited by 175
DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
Jin, X., Yan, Y., Wang, D., Ding, D., Ma, T., Ye, Z., Jiménez, R. E., Wang, L., Wu, H., & Huang, H. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.036 · Cited by 169
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Cato, L., de Tribolet-Hardy, J., Lee, I. I., Rottenberg, J. T., Coleman, I. M., Melchers, D., Houtman, R., Xiao, T., Li, W., Uo, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.008 · Cited by 171
Self-citationTranslating cancer genomes and transcriptomes for precision oncology
Roychowdhury, S., & Chinnaiyan, A. M. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21329 · Cited by 168
Self-citationZhang, Z., Zhou, C., Li, X., Barnes, S. D., Deng, S., Hoover, E., Chen, C.-C., Lee, Y. S., Zhang, Y., Wang, C., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.001 · Cited by 167
Self-citationTargeting the Androgen Signaling Axis in Prostate Cancer
Dai, C. S., Dehm, S. M., & Sharifi, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00433 · Cited by 182
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
Yasumizu, Y., Rajabi, H. N., Jin, C., Hata, T., Pitroda, S. P., Long, M. D., Hagiwara, M., Li, W., Hu, Q., Liu, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14219-6 · Cited by 167
Komura, K., Jeong, S. H., Hinohara, K., Qu, F., Wang, X., Hiraki, M., Azuma, H., Lee, G. M., Kantoff, P. W., & Sweeney, C. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600420113 · Cited by 165
Self-citationTargeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
Qiao, Y., Wang, X., Mannan, R., Pitchiaya, S., Zhang, Y., Wotring, J. W., Xiao, L., Robinson, D. R., Wu, Y., Tien, J. C.-Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021450118 · Cited by 169
Self-citationPatient-derived xenografts and organoids model therapy response in prostate cancer
Karkampouna, S., Manna, F. L., Benjak, A., Kiener, M., Menna, M. D., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21300-6 · Cited by 162
Self-citationUlz, P., Belic, J., Graf, R., Auer, M., Lafer, I., Fischereder, K., Webersinke, G., Pummer, K., Augustin, H., Pichler, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12008 · Cited by 159
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Wagner, A. H., Devarakonda, S. H. K., Skidmore, Z. L., Krysiak, K., Ramu, A., Trani, L., Kunisaki, J., Masood, A., Waqar, S. N., Spies, N. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06162-9 · Cited by 160
Self-citationProspective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
Chung, J., Dewal, N., Sokol, E. S., Mathew, P. F., Whitehead, R. P., Millis, S. Z., Frampton, G. M., Bratslavsky, G., Pal, S. K., Lee, R. J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00283 · Cited by 166
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Boudadi, K., Suzman, D. L., Anagnostou, V., Fu, W., Luber, B. S., Wang, H., Niknafs, N., White, J. R., Silberstein, J. L., Sullivan, R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25564 · Cited by 160
Self-citationAsangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J. F., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y.-C., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 162
Self-citationHaffner, M. C., Güner, G., Taheri, D., Netto, G. J., Palsgrove, D. N., Zheng, Q., Guedes, L. B., Kim, K., Tsai, H. K., Esopi, D., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.02.014 · Cited by 160
Self-citationDiverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
Chen, Z., Wu, D., Thomas‐Ahner, J. M., Lu, C., Zhao, P., Zhang, Q., Geraghty, C. M., Yan, P. S., Hankey, W., Sunkel, B. D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718811115 · Cited by 157
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira, S., Porta, N., Arce‐Gallego, S., Seed, G., Llop‐Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C. M., Baker, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0007 · Cited by 158
Self-citationMSH2 Loss in Primary Prostate Cancer
Guedes, L. B., Antonarakis, E. S., Schweizer, M. T., Mirkheshti, N., Almutairi, F., Park, J. C., Glavaris, S. A., Hicks, J. L., Eisenberger, M. A., Marzo, A. M. D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0955 · Cited by 158
Self-citationKohli, M., Ho, Y., Hillman, D. W., Etten, J. L. V., Henzler, C. M., Yang, R., Sperger, J. M., Li, Y., Tseng, E., Hon, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0017 · Cited by 157
Welti, J. C., Sharp, A., Yuan, W., Dolling, D. I., Rodrigues, D. N., Figueiredo, I., Gil, V., Neeb, A., Clarke, M., Seed, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3571 · Cited by 154
Self-citationLi, G., Choi, J. E., Kryczek, I., Sun, Y., Liao, P., Li, S., Wei, S., Grove, S., Vatan, L., Nelson, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.008 · Cited by 161
Self-citationLandscape of gene fusions in epithelial cancers: seq and ye shall find
Kumar‐Sinha, C., Sundaram, S. K., & Chinnaiyan, A. M. (2015) · Genome Medicine · doi:10.1186/s13073-015-0252-1 · Cited by 156
Self-citationJin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0314 · Cited by 153
Rodríguez-Bravo, V., Pippa, R., Song, W.-M., Carceles‐Cordon, M., Dominguez-Andres, A., Fujiwara, N., Woo, J., Koh, A. P., Ertel, A., Lokareddy, R. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.015 · Cited by 153
Landscape of Noncoding RNA in Prostate Cancer
Hua, J. T., Chen, S., & He, H. H. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.08.004 · Cited by 152
Levenshtein Distance, Sequence Comparison and Biological Database Search
Berger, B., Waterman, M. S., & Yu, Y. W. (2020) · IEEE Transactions on Information Theory · doi:10.1109/tit.2020.2996543 · Cited by 174
An, J., Ren, S., Murphy, S. J., Dalangood, S., Chang, C., Pang, X., Cui, Y., Wang, L., Pan, Y., Zhang, X., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.025 · Cited by 154
McKay, R. R., Ye, H., Xie, W., Lis, R. T., Calagua, C., Zhang, Z., Trinh, Q., Chang, S. L., Harshman, L. C., Ross, A. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01777 · Cited by 152
Self-citationTrop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905384117 · Cited by 146
Self-citationCellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 169
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
Mota, J. M., Barnett, E. S., Nauseef, J. T., Nguyen, B., Stopsack, K. H., Wibmer, A. G., Flynn, J. R., Heller, G., Danila, D. C., Rathkopf, D. E., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00346 · Cited by 153
Self-citationThe Heterogeneity of Prostate Cancer: A Practical Approach
Tolkach, Y., & Kristiansen, G. (2018) · Pathobiology · doi:10.1159/000477852 · Cited by 157
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
Cyrta, J., Augspach, A., Filippo, M. R. D., Prandi, D., Thienger, P., Benelli, M., Cooley, V., Bareja, R., Wilkes, D. C., Chae, S.-S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19328-1 · Cited by 153
Self-citationMolecules in medicine mini-review: isoforms of PI3K in biology and disease
Vanhaesebroeck, B., Whitehead, M., & Piñeiro, R. (2015) · Journal of molecular medicine · doi:10.1007/s00109-015-1352-5 · Cited by 127
Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer
Eggener, S. E., Yousuf, A. N., Watson, S., Wang, S., & Oto, A. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.07.074 · Cited by 147
Prostate cancer and PARP inhibitors: progress and challenges
Teyssonneau, D., Margot, H., Cabart, M., Anonnay, M., Sargos, P., Vuong, N., Soubeyran, I., Sévenet, N., & Roubaud, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01061-x · Cited by 154
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02704-x · Cited by 154
“…was not enriched for patients with BRCA1/BRCA2 alterations, which were well balanced between the treatment arms (talazoparib group, 36%; placebo group, 42%); the observed BRCA1/BRCA2 prevalence in the prospectively determined HRR-deficient population was in line with previous reports 5,7,8 .”
The molecular and cellular origin of human prostate cancer
Packer, J. R., & Maitland, N. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.02.016 · Cited by 161
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 149
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Patnaik, A., Swanson, K. D., Csizmadia, E., Solanki, A., Landon‐Brace, N., Gehring, M. P., Helenius, K., Olson, B. M., Pyzer, A. R., Wang, L. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0778 · Cited by 146
Self-citationMateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S., Swales, K. E., Decordova, S., DeYoung, M. P., Smith, D. A., Sundaram, S. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0725 · Cited by 149
Self-citationOh, M., Alkhushaym, N., Fallatah, S., Althagafi, A. A., Aljadeed, R., Alsowaida, Y. S., Jeter, J., Martin, J. R., Babiker, H. M., McBride, A., et al. (2019) · The Prostate · doi:10.1002/pros.23795 · Cited by 151
Li, X., Baek, G., Ramanand, S. G., Sharp, A., Gao, Y., Yuan, W., Welti, J., Rodrigues, D. N., Dolling, D., Figueiredo, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.078 · Cited by 148
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Boysen, G., Rodrigues, D. N., Rescigno, P., Seed, G., Dolling, D., Riisnaes, R., Crespo, M., Zafeiriou, Z., Sumanasuriya, S., Bianchini, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0937 · Cited by 145
Self-citationBiological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
Self-citationProstate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 149
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response
Ashrafizadeh, M., Paskeh, M. D. A., Mirzaei, S., Gholami, M. H., Zarrabi, A., Hashemi, F., Hushmandi, K., Hashemi, M., Nabavi, N., Crea, F., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02293-6 · Cited by 150
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05084-1 · Cited by 152
Self-citationTRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression
Fong, K.-W., Zhao, J. C., Song, B., Zheng, B., & Yu, J. (2018) · Nature Communications · doi:10.1038/s41467-018-07475-5 · Cited by 147
Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Chakravarty, D., Nair, S. S., Hammouda, N., Ratnani, P., Gharib, Y., Wagaskar, V. G., Mohamed, N., Lundon, D., Dovey, Z. S., Kyprianou, N., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1088-9 · Cited by 145
Wang, S., Li, H., Song, M., He, Z., Wu, T., Wang, X., Tao, Z., Wu, K., & Liu, X. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009557 · Cited by 151
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 143
Self-citationKregel, S., Wang, C., Han, X., Xiao, L., Fernández‐Salas, E., Bawa, P., McCollum, B. L., Wilder-Romans, K., Apel, I. J., Cao, X., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2019.12.003 · Cited by 144
Self-citationDevelopment and prevalence of castration-resistant prostate cancer subtypes
Vellky, J. E., & Ricke, W. A. (2020) · Neoplasia · doi:10.1016/j.neo.2020.09.002 · Cited by 152
Audet‐Walsh, É., Dufour, C. R., Yee, T., Zouanat, F. Z., Yan, M., Kalloghlian, G., Vernier, M., Caron, M., Bourque, G., Scarlata, E., et al. (2017) · Genes & Development · doi:10.1101/gad.299958.117 · Cited by 142
Laere, B. D., van Dam, P., Whitington, T., Mayrhofer, M., Diaz, E. H., den Eynden, G. V., Vandebroek, J., Del‐Favero, J., Laere, S. V., Dirix, L. Y., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.01.011 · Cited by 141
Velho, P. I., Silberstein, J. L., Markowski, M. C., Luo, J., Lotan, T. L., Isaacs, W. B., & Antonarakis, E. S. (2018) · The Prostate · doi:10.1002/pros.23484 · Cited by 139
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 138
Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition
Wang, C., Wang, G., Feng, X., Shepherd, P. D. A., Zhang, J., Tang, M., Chen, Z., Srivastava, M., McLaughlin, M. E., Navone, N. M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0606-4 · Cited by 142
Mayrhofer, M., Laere, B. D., Whitington, T., Oyen, P. V., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D. L. A. L., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0595-5 · Cited by 141
ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
Tang, Z., Pilie, P. G., Geng, C., Manyam, G. C., Yang, G., Park, S., Wang, D., Peng, S., Wu, C., Peng, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1010 · Cited by 142
Altered Signaling Pathways in Prostate Cancer Drive Metabolic Fate
Antico Arciuch, V. G., Gueron, G., Cotignola, J. H., & Vazquez, E. S. (2017) · CONICET Digital (CONICET) · Cited by 139
Popova, T., Manié, E., Boeva, V., Battistella, A., Goundiam, O., Smith, N. K., Mueller, C. R., Raynal, V., Mariani, O., Sastre-Garau, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2128 · Cited by 130
Precision oncology in the age of integrative genomics
Kumar‐Sinha, C., & Chinnaiyan, A. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4017 · Cited by 138
Self-citationClinical relevance of androgen receptor alterations in prostate cancer
Jernberg, E., Bergh, A. R. J., & Wikström, P. (2017) · Endocrine Connections · doi:10.1530/ec-17-0118 · Cited by 140
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
